lutetium (177Lu) oxodotreotide

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Lutathera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Lutathera.

For practical information about using Lutathera, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 13/02/2023

Authorisation details

Product details
Agency product number
Active substance
lutetium (177Lu) oxodotreotide
International non-proprietary name (INN) or common name
lutetium (177Lu) oxodotreotide
Therapeutic area (MeSH)
Neuroendocrine Tumors
Anatomical therapeutic chemical (ATC) code

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Advanced Accelerator Applications
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Advanced Accelerator Applications
8-10 Rue Henri Sainte-Claire Deville
92500 Rueil-Malmaison

Product information

10/02/2023 Lutathera - EMEA/H/C/004123 - IAIN/0041

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other therapeutic radiopharmaceuticals

Therapeutic indication

Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP‑NETs) in adults.

Assessment history

Related content

How useful was this page?

Add your rating
6 ratings
1 rating
1 rating